MedTrace Logo

Safety and Retention Rate of the JAK and TNF Inhibitors in Rheumatoid Arthritis: a Real-life Experience

NCT05182203 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1732

Last updated 2023-02-22

No results posted yet for this study

Summary

This study aims to extract data from the Hong Kong Biologics Registry for retention rate of the JAK inhibitors in rheumatoid arthritis and review other adverse events by looking at the medical record retrospectively. These real life data are important as they cannot be provided by randomized controlled trials which are limited by the duration of observation and fixed protocols in research settings. Moreover, data will represent our local experience of the JAK inhibitors in Chinese patients with RA. The retention rate and adverse effects of the JAK inhibitors are compared with conventional TNF inhibitors.

Conditions

Interventions

DRUG

biologic/targeted therapy

TNF inhibitors or the JAK inhibitors

Sponsors & Collaborators

  • Tuen Mun Hospital

    lead OTHER_GOV

Principal Investigators

  • Chi Chiu Mok, MD, FRCP · Tuen Mun Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2022-09-01
Completion
2022-10-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05182203 on ClinicalTrials.gov